Nexlizet is a Oral Tablet, Film Coated in the Human Prescription Drug category. It is labeled and distributed by Esperion Therapeutics, Inc.. The primary component is Bempedoic Acid; Ezetimibe.
| Product ID | 72426-818_5dd83231-830c-482c-a341-d88c77c50c74 |
| NDC | 72426-818 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Nexlizet |
| Generic Name | Bempedoic Acid And Ezetimibe |
| Dosage Form | Tablet, Film Coated |
| Route of Administration | ORAL |
| Marketing Start Date | 2020-03-09 |
| Marketing Category | NDA / NDA |
| Application Number | NDA211617 |
| Labeler Name | Esperion Therapeutics, Inc. |
| Substance Name | BEMPEDOIC ACID; EZETIMIBE |
| Active Ingredient Strength | 180 mg/1; mg/1 |
| Pharm Classes | Decreased Cholesterol Absorption [PE],Dietary Cholesterol Absorption Inhibitor [EPC] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2021-12-31 |
| Marketing Start Date | 2020-03-09 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA211617 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2020-03-09 |
| Marketing Category | NDA |
| Application Number | NDA211617 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2020-03-09 |
| Marketing Category | NDA |
| Application Number | NDA211617 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2020-03-09 |
| Ingredient | Strength |
|---|---|
| BEMPEDOIC ACID | 180 mg/1 |
| SPL SET ID: | 3fa2108c-0300-47b8-9d34-f762af7c93c6 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI | |
| UPC Code |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() NEXLIZET 88145092 not registered Live/Pending |
Esperion Therapeutics, Inc. 2018-10-05 |